“A new University of California San Diego study offers compelling evidence that GLP-1 receptor agonists — the class of drugs behind Ozempic, Wegovy and Mounjaro, for example — may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who weren’t on the drugs (15.5% vs. 37.1%).

The study, led by Raphael Cuomo, Ph.D., associate professor in the Department of Anesthesiology at UC San Diego School of Medicine and member of UC San Diego Moores Cancer Center, used real-world clinical data from the University of California Health Data Warehouse to assess outcomes across the state’s academic medical centers. After adjusting for age, body mass index (BMI), disease severity and other health factors, GLP-1 users still showed significantly lower odds of death, suggesting a strong and independent protective effect.”

From UC San Diego Today.